Edition:
India

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

89.63USD
21 Mar 2019
Change (% chg)

-- (--)
Prev Close
$89.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,925,412
52-wk High
$95.30
52-wk Low
$58.61

Chart for

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $108,911.00
Shares Outstanding(Mil.): 782.35
Dividend: --
Yield (%): --

Financials

  CELG.OQ Industry Sector
P/E (TTM): 43.29 29.30 32.54
EPS (TTM): 3.22 -- --
ROI: 10.08 14.23 13.82
ROE: 37.19 15.46 15.25

U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.

14 Mar 2019

UPDATE 1-U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

March 14 The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.

14 Mar 2019

U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid

March 14 A U.S. administrative court on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.

14 Mar 2019

Third Point holds Celgene stock, in bet Bristol-Myers deal will close: source

Daniel Loeb's hedge fund Third Point LLC owns a small stake in Celgene Corp, betting that the proposed $74 billion sale of the biotechnology company to Bristol-Myers Squibb Co will be completed, a person familiar with the matter said on Monday.

12 Mar 2019

Third Point holds Celgene stock, in bet Bristol-Myers deal will close -source

March 11 Daniel Loeb's hedge fund Third Point LLC owns a small stake in Celgene Corp, betting that the proposed $74 billion sale of the biotechnology company to Bristol-Myers Squibb Co will be completed, a person familiar with the matter said on Monday.

12 Mar 2019

Starboard builds stake in Zayo, presses for sale

Activist hedge fund Starboard Value LP has amassed a 4 percent stake in Zayo Group Holdings Inc and is asking the U.S. communications infrastructure provider to consider a sale, according to a letter sent by Starboard to Zayo on Thursday.

08 Mar 2019

UPDATE 2-Starboard builds stake in Zayo, presses for sale

March 7 Activist hedge fund Starboard Value LP has amassed a 4 percent stake in Zayo Group Holdings Inc and is asking the U.S. communications infrastructure provider to consider a sale, according to a letter sent by Starboard to Zayo on Thursday.

08 Mar 2019

Starboard builds stake in Zayo, presses for sale

March 7 Activist hedge fund Starboard Value LP has amassed a 4 percent stake in Zayo Group Holdings Inc and is asking the U.S. communications infrastructure provider to consider a sale, according to a letter sent by Starboard to Zayo on Thursday.

07 Mar 2019

Bristol-Myers defends Celgene bet as investor criticism grows

Bristol-Myers Squibb defended its planned $74 billion takeover of Celgene Corp, saying it had carried out a "robust" assessment of the merger after two major investors opposed what could be the largest pharmaceutical deal ever.

06 Mar 2019

Bristol-Myers defends Celgene bet as investor criticism grows

Bristol-Myers Squibb defended its planned $74 billion takeover of Celgene Corp, saying it had carried out a "robust" assessment of the merger after two major investors opposed what could be the largest pharmaceutical deal ever.

06 Mar 2019

Earnings vs. Estimates